CannLabs, Inc. (CANL) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は Denver, CO, アメリカ. 現CEOは Mark C. Mirken.
CANL を有する IPO日 2014-06-13, 37 名の正社員, に上場 Other OTC, 時価総額 $93.32K.
CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. is based in Denver, Colorado.
